Home › Trials › NCT04107766

Registry for patients undergoing microwave ablation for liver cancer

A Multicenter Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions

Observational Ethicon, Inc. · NCT04107766

This study is tracking up to 1,500 patients who have had microwave ablation for liver cancer to see how well the treatment works and to improve future care.

Quick facts

Study typeObservational
Enrollment1500 (estimated)
Ages22 Years and up
SexAll
SponsorEthicon, Inc. Industry-sponsored
Locations30 sites (Loma Linda, California and 29 other locations)
Trial IDNCT04107766 on ClinicalTrials.gov

What this trial studies

This multicenter observational registry follows patients for five years after their first liver ablation procedure using the NEUWAVE Microwave Ablation System. It collects data from various participating sites to analyze and develop guidance on ablation parameters tailored to different liver tissue conditions and lesions. The registry includes both prospective and retrospective patient data, aiming to enroll up to 1,500 patients worldwide who have undergone or are scheduled for this treatment.

Who should consider this trial

Good fit: Ideal candidates are patients aged 22 and older who are undergoing microwave ablation for liver lesions using the NEUWAVE system.

Not a fit: Patients with a life expectancy of less than one year or those using microwave ablation solely as a transection tool may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could enhance the understanding of microwave ablation techniques, leading to improved treatment outcomes for liver cancer patients.

How similar studies have performed: Other studies utilizing observational registries for similar ablation techniques have shown promise, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Patients who underwent or are scheduled to undergo a microwave ablation of one or more liver lesions with the NEUWAVE Microwave Ablation System per the device's Instructions for Use (IFU).
2. Patients with signed informed consent (or waiver approved by IRB/EC) who are willing to comply with the assessment schedule, and willing to have data included in the database.
3. Patients greater than or equal to 22 years old at the time of informed consent (or waiver approved by IRB/EC).

Exclusion Criteria:

1. Patients with a life expectancy of less than 1 year, in the opinion of the treating physician.
2. Use of microwave ablation purely as a transection tool, rather than focused liver lesion ablation.
3. Patient is currently participating, or planning to participate, in another NeuWave/Ethicon-funded clinical trial or registry studying microwave ablation in the liver. Note: roll-over patients from previous NeuWave trials are permitted.

Where this trial is running

Loma Linda, California and 29 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Cancer of the LiverLiver CancerNeoplasms, Liver
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.